Delhi High Court’s reversal of Novartis injunction provides further guidance on India’s controversial Section 3(d) requirement
Shutterstock/Taljat David
Pendulum swings in favour of local generic drugmaker Natco in long-running Indian pharma dispute against Novartis
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
